These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8814058)

  • 1. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
    Pryor BD; Bologna SG; Kahl LE
    Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort.
    Yang SC; Lai YY; Huang MC; Tsai CS; Wang JL
    Lupus; 2018 Oct; 27(11):1819-1827. PubMed ID: 30103646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe infections in plasmapheresis-treated systemic lupus erythematosus.
    Aringer M; Smolen JS; Graninger WB
    Arthritis Rheum; 1998 Mar; 41(3):414-20. PubMed ID: 9506568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
    Shao M; Guo HF; Lei LY; Zhao Q; Ding YJ; Lin J; Wu R; Yu F; Li YC; Miao HL; Zhang LY; DU Y; Jiao RY; Pang LX; Long L; Li ZG; Li R
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1112-1116. PubMed ID: 36533341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease.
    Yuan S; Ye Y; Chen D; Qiu Q; Zhan Z; Lian F; Li H; Liang L; Xu H; Yang X
    Semin Arthritis Rheum; 2014 Jun; 43(6):759-66. PubMed ID: 24332116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.
    Opastirakul S; Chartapisak W
    Pediatr Nephrol; 2005 Dec; 20(12):1750-5. PubMed ID: 16133037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
    Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
    Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximum tolerable dose of cyclophosphamide and azathioprine in Pakistani patients with primary renal disease.
    Ali SS; Rabbani MA; Moinuddin SS; Virani S; Farooque F; Salam A; Ahmad A
    J Pak Med Assoc; 2004 Jan; 54(1):39-42. PubMed ID: 15058645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
    Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.
    Danza A; Ruiz-Irastorza G
    Lupus; 2013 Oct; 22(12):1286-94. PubMed ID: 24098001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
    Feldman CH; Marty FM; Winkelmayer WC; Guan H; Franklin JM; Solomon DH; Costenbader KH; Kim SC
    Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome.
    Garcia-Vives E; Segarra-Medrano A; Martinez-Valle F; Agraz I; Solans-Laque R
    J Rheumatol; 2020 Mar; 47(3):407-414. PubMed ID: 31203229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection in systemic lupus erythematosus.
    Janwityanuchit S; Totemchokchyakarn K; Krachangwongchai K; Vatanasuk M
    J Med Assoc Thai; 1993 Oct; 76(10):542-8. PubMed ID: 7964223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
    Garnier C; Ribes D; Chauveau D; Huart A; Pugnet G; Adoue D; Prevot G; Alric L; Delobel P; Derumeaux H; Mengelle C; Sailler L; Moulis G
    J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.